Shin Nippon Biomedical Laboratories, Ltd. (JP:2395) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shin Nippon Biomedical Laboratories reported a 5.3% increase in revenue for the six months ending September 2024, reaching 12,508 million yen, despite a significant drop in operating profit by 96.6%. The company’s net assets grew to 36,453 million yen, although the equity ratio decreased to 40.9%. Dividends for the fiscal year are forecasted to remain stable at 50 yen per share.
For further insights into JP:2395 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- ‘The Big Vote Coming’: Daniel Ives Weighs In on Tesla Stock as Shareholders Decide Musk’s $1 Trillion Pay Package
- ‘Time to Get Off This Train,’ Says Top Analyst About Rigetti Computing Stock Ahead of Earnings
- AMD Stock Heads Into Tuesday’s Earnings With Momentum — Here’s What This Top Investor Expects